MedTrace Logo

Evaluation of the ctDNA LUNAR Test in an Average Patient Screening Episode

NCT04136002 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 44467

Last updated 2026-05-14

No results posted yet for this study

Summary

The ECLIPSE (Evaluation of the ctDNA LUNAR test in an Average Patient Screening Episode) study is a prospective, observational multi-site study without randomization. The primary objective of the study is to evaluate the performance characteristics of a blood-based ctDNA LUNAR-2 test to detect colorectal cancer in a screen-relevant, average risk population.

Conditions

Sponsors & Collaborators

  • Premier Research

    collaborator OTHER

  • Guardant Health, Inc.

    lead INDUSTRY

Principal Investigators

  • Craig Eagle, MD · Guardant Health, Inc.

Eligibility

Min Age
45 Years
Max Age
84 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2019-10-08
Primary Completion
2024-03-20
Completion
2027-08-05

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04136002 on ClinicalTrials.gov